Mediators of Inflammation

Mediators of Inflammation / 2002 / Article

Open Access

Volume 11 |Article ID 219857 | https://doi.org/10.1080/09622935020138226

Gabriele Di Lorenzo, Maria Luisa Pacor, Maria Esposito Pellitteri, Sebastiano Gangemi, Patrizia Di Blasi, Giuseppina Candore, Alfredo Colombo, Domenico Lio, Calogero Caruso, "In vitro effects of fluticasone propionate on IL-13 production by mitogen-stimulated lymphocytes", Mediators of Inflammation, vol. 11, Article ID 219857, 4 pages, 2002. https://doi.org/10.1080/09622935020138226

In vitro effects of fluticasone propionate on IL-13 production by mitogen-stimulated lymphocytes

Abstract

Background: Corticosteroid administration produces multiple immunomodulatory effects, including down-regulation of cytokine production by CD4 T lymphocytes. Fluticasone propionate (FP) (Glaxo Smith&Kline, Greenford, UK), a highly lipophilic topical corticosteroid, has been shown to be safe and effective in the treatment of asthma and of both seasonal and perennial rhinitis.Aims: To gain insight into the mechanisms of FP therapeutic effects, we evaluated interleukin (IL)-13 (a type 2 cytokine that seemingly plays a pivotal role in allergic mechanisms) production by mitogen-stimulated peripheral blood mononuclear cells (MNC) in vitro, treated or not with FP.Methods: MNC from 10 healthy subjects and 10 asthmatic atopic patients with Parietaria allergy were stimulated v/v with phytohaemagglutinin (PHA) (50 γ/ml) or with complete medium alone as a control. Culture supernatants, in vitro treated or not with 10-7 or 10-8 M FP, were collected after 48 or 72 h incubation. IL-13 production was assessed by enzyme-linked immunosorbent assay. In random selected samples, after 4 or 24 h of cell cultures, RNA was extracted and IL-4 and IL-5 reverse transcriptase-polymerase chain reaction (RT-PCR) products analyzed.Results: At 48 h, there were no differences in IL-13 concentration in PHA-stimulated cultures between healthy subjects and asthmatic patients (93.6 ± 18.9 versus 111.0 ± 25.1 pg/ml). At 72 h, similar results were obtained (63.9 ± 3.0 versus 73.3 ± 2.5 pg/ml, respectively). At this time, however, IL-13 concentrations were significantly decreased versus 48 h both in asthmatics (p<0.001) and in controls (p<0.001). Treatment with 10-7 M FP significantly reduced IL-13 production in healthy subjects and asthmatic patients both at 48 h (93.6 ± 18.9 versus 50.50 ± 10.6 pg/ml, p<0.001, and 111.0 ± 25.1 versus 59.3 ± 13.6 pg/ml, p<0.001, respectively) and at 72 h (63.9 ± 9.6 versus 35.5 ± 4.4 pg/ml, p<0.001, and 73.3 ± 8.0 versus 40.7 ± 4.5 pg/ml, p<0.001, respectively). Similar results were obtained with 10-8 M FP at 48 and 72 h. Accordingly, evaluation of RT-PCR products from selected cell samples showed a FP dosage-dependent inhibition of IL-4 and IL-5 mRNA production both for healthy subjects and asthmatic patients.Conclusions: FP in vitro impairs IL-13 production by PHA-stimulated MNC from asthmatic and control subjects. This strengthens previous suggestions that IL-13 inhibition by steroids may, at least in part, account for their therapeutic effects.

Copyright © 2002 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views90
Downloads324
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.